Mentioned:
The Netherlands are embracing MDMA for clinical trials. And they’re turning to a publicly traded company in Canada to do it.
What’s happening:
- PharmAla Biotech (CSE: MDMA) has announced they have struck a new deal with pharmaceutical wholesale company Duchefa Farma to become their exclusive distributor of their proprietary LaNeo MDMA in the Netherlands
Why it matters:
- This is the first distribution deal PharmAla Biotech has ever entered into to bring their pharmaceutical grade MDMA compounds into the Netherlands
Going deeper:
- PharmaAla Biotech has been aggressively ramping up distribution partnerships lately, including a notable deal to supply MDMA for an upcoming clinical trial taking place at Yale University
- MDMA as a therapeutic treatment has also continued to make meaningful progress globally, fuelled largely by new research studies and clinical trials beginning to receive funding from both publicly listed companies and even the American government
